Volume 1 Supplement 1

Abstracts of the 50th Workshop for Pediatric Research

Open Access

Cardiac FGF23 expression correlates with left ventricular hypertrophy in patients with chronic kidney disease

  • Maren Leifheit-Nestler1,
  • Robert Große Siemer1,
  • Kathrin Flasbart1,
  • Dagmar-Christiane Fischer2,
  • Michael Klintschar3,
  • Jan U Becker4,
  • Christoph Aufricht5,
  • Tomas Seeman6 and
  • Dieter Haffner1
Molecular and Cellular Pediatrics20141(Suppl 1):A25

https://doi.org/10.1186/2194-7791-1-S1-A25

Published: 11 September 2014

Left ventricular hypertrophy (LVH) is the most common cardiac abnormality in children with CKD. Experimental and clinical studies demonstrated an association between elevated serum levels of fibroblast growth factor 23 (FGF23) and LVH in CKD. The aim of our study was to investigate i) the endogenous expression of FGF23 in heart tissue of paediatric CKD patients, ii) to establish the relationship between cardiac FGF23 expression and typical molecular mechanisms for LVH, and iii) to evaluate whether cardiac FGF23 expression is associated with LVH and other clinical parameters.

We conducted a retrospective case-control-study in 25 deceased paediatric patients (age 11±8y) with CKD stage 5 and 25 age and sex-matched healthy controls. Myocardial autopsy samples of the left ventricle (LV) were evaluated by immunohistochemistry and qPCR with respect to endogenous FGF23 expression, calcineurin-NFAT signalling, genes regulating cardiac remodelling, and brain natriuretic peptide (BNP) as a marker of LVH.

Cardiac FGF23 expression increased in CKD patients compared to controls (p<0.01), and correlated with LVH demonstrated by enhanced BNP expression as well as increased cardiomyocyte cross-sectional area (each p<0.01). The calcineurin expression significantly enhanced in cardiac tissue of CKD patients presenting with LVH (p<0.05), and cardiac remodelling was confirmed by the enhanced expression of skeletal α-actin and the significant reduction of cardiac α-actin compared to controls (p<0.05). In the patient cohort, cardiac FGF23 expression negatively correlated with the eGFR (r=-0.526), and positively correlated with time-averaged serum phosphate levels (r=0.503, each p<0.05). Likewise, cardiac FGF23 expression was not increased in transplanted patients compared to controls.

For the first time, endogenous FGF23 expression was detected in myocardial tissue. Cardiac FGF23 expression as well as the FGF23 signalling pathway mediating cardiac hypertrophy and hypertrophic gene programs were induced in LVH positive CKD patients. We conclude that, in extension to circulating FGF23 levels, both, endogenous and circulating FGF23 contribute to LVH in CKD.

Authors’ Affiliations

(1)
Department of Paediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School
(2)
Department of Paediatrics, University Hospital Rostock
(3)
Institute for Forensic Medicine, Hannover Medical School
(4)
Institute of Pathology, Hannover Medical School
(5)
Division of Paediatric Nephrology, University Children’s Hospital Vienna
(6)
Division of Paediatric Nephrology, University Children’s Hospital Motol

Copyright

© Leifheit-Nestler et al; licensee Springer 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.